Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

CLONEMESI is an academic, independent, randomized placebo-controlled trial to assess the effect of transdermal (TD) clonidine in improving the symptoms of severe Hyperemesis Gravidarum(HG) affecting women in their 6th-12th week of pregnancy. The study has a crossover design.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Azienda Ospedaliera Città della Salute e della Scienza di Torino
• Treatments: Clonidine

Criteria

Inclusion Criteria:

• Gestational age 6-12 weeks and a major grade of HG clinical severity defined as follows:

• a PUQE score index ≥ 13 associated to one or more of the following conditions:

• weight loss > 5% of pregravidic weight,

• electrolyte disturbances,

• dehydration,

• duration of symptoms > 10 days ,

• inadequate food and drink intake

Exclusion Criteria:

• Language barrier.